Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG GENES KEGG PATHWAY KEGG DRUG DrugBank Disease ID
1 CYSLTR1 [2] Calcium signaling pathway, Neuroactive ligand-receptor interaction D00529 Montelukast [8] 6, 13, 46, 61, 63, 85, 98, 228
2 CYSLTR1 [2] Calcium signaling pathway, Neuroactive ligand-receptor interaction D01385 Ibudilast [2] 2, 13
3 CYSLTR1 [2] Calcium signaling pathway, Neuroactive ligand-receptor interaction D06659 Tipelukast [1] 85
4 CYSLTR1 [2] Calcium signaling pathway, Neuroactive ligand-receptor interaction D08229 Montelukast [8] 6, 13, 46, 61, 63, 85, 98, 228
5 CHRM1 [7] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D00113 Atropine [2] 2, 299
6 CHRM1 [7] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D00138 Scopolamine [1] 2
7 CHRM1 [7] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D00270 Chlorpromazine [1] 254
8 CHRM1 [7] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D00397 Tropicamide [3] 6, 13, 19
9 CHRM1 [7] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D00465 Oxybutynin [3] 6, 13, 53
10 CHRM1 [7] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D00481 Propantheline [1] 26
11 CHRM1 [7] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D00722 Oxybutynin [3] 6, 13, 53
12 CHRM1 [7] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D00765 Rocuronium [1] 296
13 CHRM1 [7] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D00787 Trihexyphenidyl [2] 5, 6
14 CHRM1 [7] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D00789 Chlorpromazine [1] 254
15 CHRM1 [7] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D01000 Bethanechol [1] 98
16 CHRM1 [7] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D01077 Atropine [2] 2, 299
17 CHRM1 [7] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D02069 Atropine [2] 2, 299
18 CHRM1 [7] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D02212 Ipratropium [2] 6, 86
19 CHRM1 [7] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D03011 Atropine [2] 2, 299
20 CHRM1 [7] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D03274 Chlorpromazine [1] 254
21 CHRM1 [7] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D03814 Atropine [2] 2, 299
22 CHRM1 [7] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D04034 Chlorpromazine [1] 254
23 CHRM1 [7] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D08441 Propiverine [1] 226
24 CHRM1 [7] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D08638 Trihexyphenidyl [2] 5, 6
25 CHRM1 [7] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D11383 Blarcamesine [1] 156
26 CHRM2 [6] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton D00113 Atropine [2] 2, 299
27 CHRM2 [6] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton D00138 Scopolamine [1] 2
28 CHRM2 [6] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton D00270 Chlorpromazine [1] 254
29 CHRM2 [6] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton D00397 Tropicamide [3] 6, 13, 19
30 CHRM2 [6] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton D00465 Oxybutynin [3] 6, 13, 53
31 CHRM2 [6] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton D00481 Propantheline [1] 26
32 CHRM2 [6] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton D00525 Pilocarpine [3] 6, 53, 299
33 CHRM2 [6] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton D00722 Oxybutynin [3] 6, 13, 53
34 CHRM2 [6] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton D00765 Rocuronium [1] 296
35 CHRM2 [6] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton D00787 Trihexyphenidyl [2] 5, 6
36 CHRM2 [6] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton D00789 Chlorpromazine [1] 254
37 CHRM2 [6] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton D01000 Bethanechol [1] 98
38 CHRM2 [6] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton D01077 Atropine [2] 2, 299
39 CHRM2 [6] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton D02069 Atropine [2] 2, 299
40 CHRM2 [6] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton D02200 Pilocarpine [3] 6, 53, 299
41 CHRM2 [6] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton D02212 Ipratropium [2] 6, 86
42 CHRM2 [6] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton D03011 Atropine [2] 2, 299
43 CHRM2 [6] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton D03274 Chlorpromazine [1] 254
44 CHRM2 [6] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton D03814 Atropine [2] 2, 299
45 CHRM2 [6] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton D04034 Chlorpromazine [1] 254
46 CHRM2 [6] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton D05478 Pilocarpine [3] 6, 53, 299
47 CHRM2 [6] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton D07226 Fesoterodine [1] 6
48 CHRM2 [6] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton D08441 Propiverine [1] 226
49 CHRM2 [6] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton D08638 Trihexyphenidyl [2] 5, 6
50 CHRM2 [6] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton D11383 Blarcamesine [1] 156
51 CHRM3 [10] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D00113 Atropine [2] 2, 299
52 CHRM3 [10] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D00138 Scopolamine [1] 2
53 CHRM3 [10] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D00270 Chlorpromazine [1] 254
54 CHRM3 [10] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D00397 Tropicamide [3] 6, 13, 19
55 CHRM3 [10] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D00465 Oxybutynin [3] 6, 13, 53
56 CHRM3 [10] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D00481 Propantheline [1] 26
57 CHRM3 [10] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D00525 Pilocarpine [3] 6, 53, 299
58 CHRM3 [10] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D00646 Tolterodine [2] 17, 53
59 CHRM3 [10] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D00661 Cevimeline [1] 53
60 CHRM3 [10] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D00722 Oxybutynin [3] 6, 13, 53
61 CHRM3 [10] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D00765 Rocuronium [1] 296
62 CHRM3 [10] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D00787 Trihexyphenidyl [2] 5, 6
63 CHRM3 [10] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D00789 Chlorpromazine [1] 254
64 CHRM3 [10] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D01000 Bethanechol [1] 98
65 CHRM3 [10] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D01077 Atropine [2] 2, 299
66 CHRM3 [10] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D01148 Tolterodine [2] 17, 53
67 CHRM3 [10] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D01269 Solifenacin [3] 6, 13, 53
68 CHRM3 [10] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D01699 Darifenacin [2] 6, 13
69 CHRM3 [10] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D02069 Atropine [2] 2, 299
70 CHRM3 [10] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D02200 Pilocarpine [3] 6, 53, 299
71 CHRM3 [10] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D02212 Ipratropium [2] 6, 86
72 CHRM3 [10] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D03011 Atropine [2] 2, 299
73 CHRM3 [10] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D03274 Chlorpromazine [1] 254
74 CHRM3 [10] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D03654 Darifenacin [2] 6, 13
75 CHRM3 [10] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D03814 Atropine [2] 2, 299
76 CHRM3 [10] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D04034 Chlorpromazine [1] 254
77 CHRM3 [10] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D05478 Pilocarpine [3] 6, 53, 299
78 CHRM3 [10] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D07226 Fesoterodine [1] 6
79 CHRM3 [10] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D07667 Cevimeline [1] 53
80 CHRM3 [10] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D08441 Propiverine [1] 226
81 CHRM3 [10] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D08522 Solifenacin [3] 6, 13, 53
82 CHRM3 [10] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D08638 Trihexyphenidyl [2] 5, 6
83 CHRM3 [10] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D11383 Blarcamesine [1] 156
84 CHRM5 [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D00113 Atropine [2] 2, 299
85 CHRM5 [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D00138 Scopolamine [1] 2
86 CHRM5 [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D00270 Chlorpromazine [1] 254
87 CHRM5 [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D00397 Tropicamide [3] 6, 13, 19
88 CHRM5 [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D00465 Oxybutynin [3] 6, 13, 53
89 CHRM5 [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D00481 Propantheline [1] 26
90 CHRM5 [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D00722 Oxybutynin [3] 6, 13, 53
91 CHRM5 [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D00765 Rocuronium [1] 296
92 CHRM5 [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D00787 Trihexyphenidyl [2] 5, 6
93 CHRM5 [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D00789 Chlorpromazine [1] 254
94 CHRM5 [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D01000 Bethanechol [1] 98
95 CHRM5 [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D01077 Atropine [2] 2, 299
96 CHRM5 [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D02069 Atropine [2] 2, 299
97 CHRM5 [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D02212 Ipratropium [2] 6, 86
98 CHRM5 [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D03011 Atropine [2] 2, 299
99 CHRM5 [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D03274 Chlorpromazine [1] 254
100 CHRM5 [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D03814 Atropine [2] 2, 299
101 CHRM5 [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D04034 Chlorpromazine [1] 254
102 CHRM5 [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D08441 Propiverine [1] 226
103 CHRM5 [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D08638 Trihexyphenidyl [2] 5, 6
104 CHRM5 [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D11383 Blarcamesine [1] 156
105 CHRNA7 [6] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Chemical carcinogenesis - receptor activation D00765 Rocuronium [1] 296
106 CHRNA7 [6] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Chemical carcinogenesis - receptor activation D03365 Nicotine [3] 6, 13, 84
107 CHRNA7 [6] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Chemical carcinogenesis - receptor activation D05156 Nicotine [3] 6, 13, 84
108 CHRNA7 [6] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Chemical carcinogenesis - receptor activation D05157 Nicotine [3] 6, 13, 84
109 ADORA2A [6] Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease D00045 Adenosine [3] 13, 58, 65
110 ADORA2A [6] Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease D00528 Caffeine [9] 2, 6, 13, 21, 46, 78, 96, 97, 265
111 ADORA2A [6] Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease D01453 Caffeine [9] 2, 6, 13, 21, 46, 78, 96, 97, 265
112 ADORA2A [6] Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease D02017 Theophylline [2] 236, 299
113 ADORA2A [6] Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease D02769 Adenosine phosphate [1] 46
114 ADORA2A [6] Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease D04641 Istradefylline [1] 6
115 ADORA2A [6] Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease D05711 Regadenoson [1] 58
116 ADORA2A [6] Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease D09717 Preladenant [1] 6
117 ADORA2A [6] Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease D10174 Tozadenant [1] 6
118 ADORA2B [4] Rap1 signaling pathway, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction D00045 Adenosine [3] 13, 58, 65
119 ADORA2B [4] Rap1 signaling pathway, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction D00227 Aminophylline [1] 63
120 ADORA2B [4] Rap1 signaling pathway, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction D00371 Theophylline [2] 236, 299
121 ADORA2B [4] Rap1 signaling pathway, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction D01712 Theophylline [2] 236, 299
122 ADORA2B [4] Rap1 signaling pathway, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction D02769 Adenosine phosphate [1] 46
123 ADORA2B [4] Rap1 signaling pathway, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction D05429 Aminophylline [1] 63
124 ADORA2B [4] Rap1 signaling pathway, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction D06103 Theophylline [2] 236, 299
125 ADORA2B [4] Rap1 signaling pathway, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction D06104 Theophylline [2] 236, 299
126 ADRA1D [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00076 Norepinephrine [1] 22
127 ADRA1D [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00095 Epinephrine [3] 46, 70, 96
128 ADRA1D [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00124 Ephedrine [1] 11
129 ADRA1D [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00255 Carvedilol [5] 6, 57, 86, 113, 210
130 ADRA1D [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00454 Olanzapine [2] 2, 8
131 ADRA1D [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00485 Pseudoephedrine [1] 17
132 ADRA1D [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00511 Phenylephrine [1] 22
133 ADRA1D [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00608 Doxazosin [2] 57, 67
134 ADRA1D [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00610 Terazosin [1] 6
135 ADRA1D [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00636 Amiodarone [2] 28, 127
136 ADRA1D [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00680 Methylergometrine [3] 118, 280, 288
137 ADRA1D [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00996 Epinephrine [3] 46, 70, 96
138 ADRA1D [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D01277 Droxidopa [5] 5, 6, 17, 169, 170
139 ADRA1D [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D01307 Midodrine [3] 6, 17, 58
140 ADRA1D [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D02149 Epinephrine [3] 46, 70, 96
141 ADRA1D [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D02268 Ergoloid mesylate [2] 6, 206
142 ADRA1D [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D02349 Dipivefrin [1] 6
143 ADRA1D [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D02910 Amiodarone [2] 28, 127
144 ADRA1D [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D03415 Carvedilol [5] 6, 57, 86, 113, 210
145 ADRA1D [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D05206 Norepinephrine [1] 22
146 ADRA1D [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D05648 Pseudoephedrine [1] 17
147 ADRA1D [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D05649 Pseudoephedrine [1] 17
148 ADRA1D [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D06623 Olanzapine [2] 2, 8
149 ADRA1D [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D07874 Doxazosin [2] 57, 67
150 ADRA1D [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08064 Ifenprodil [1] 85
151 ADRA1D [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08207 Methylergometrine [3] 118, 280, 288
152 ADRA1D [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08220 Midodrine [3] 6, 17, 58
153 ADRA1D [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08365 Phenylephrine [1] 22
154 ADRA1D [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08449 Pseudoephedrine [1] 17
155 ADRA1D [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08569 Terazosin [1] 6
156 ADRA1B [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00076 Norepinephrine [1] 22
157 ADRA1B [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00095 Epinephrine [3] 46, 70, 96
158 ADRA1B [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00124 Ephedrine [1] 11
159 ADRA1B [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00255 Carvedilol [5] 6, 57, 86, 113, 210
160 ADRA1B [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00454 Olanzapine [2] 2, 8
161 ADRA1B [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00485 Pseudoephedrine [1] 17
162 ADRA1B [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00511 Phenylephrine [1] 22
163 ADRA1B [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00608 Doxazosin [2] 57, 67
164 ADRA1B [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00610 Terazosin [1] 6
165 ADRA1B [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00636 Amiodarone [2] 28, 127
166 ADRA1B [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00680 Methylergometrine [3] 118, 280, 288
167 ADRA1B [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00996 Epinephrine [3] 46, 70, 96
168 ADRA1B [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D01277 Droxidopa [5] 5, 6, 17, 169, 170
169 ADRA1B [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D01307 Midodrine [3] 6, 17, 58
170 ADRA1B [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D02149 Epinephrine [3] 46, 70, 96
171 ADRA1B [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D02268 Ergoloid mesylate [2] 6, 206
172 ADRA1B [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D02349 Dipivefrin [1] 6
173 ADRA1B [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D02910 Amiodarone [2] 28, 127
174 ADRA1B [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D03415 Carvedilol [5] 6, 57, 86, 113, 210
175 ADRA1B [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D05206 Norepinephrine [1] 22
176 ADRA1B [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D05648 Pseudoephedrine [1] 17
177 ADRA1B [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D05649 Pseudoephedrine [1] 17
178 ADRA1B [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D06623 Olanzapine [2] 2, 8
179 ADRA1B [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D07874 Doxazosin [2] 57, 67
180 ADRA1B [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08064 Ifenprodil [1] 85
181 ADRA1B [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08207 Methylergometrine [3] 118, 280, 288
182 ADRA1B [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08220 Midodrine [3] 6, 17, 58
183 ADRA1B [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08365 Phenylephrine [1] 22
184 ADRA1B [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08449 Pseudoephedrine [1] 17
185 ADRA1B [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08569 Terazosin [1] 6
186 ADRA1A [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00076 Norepinephrine [1] 22
187 ADRA1A [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00095 Epinephrine [3] 46, 70, 96
188 ADRA1A [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00124 Ephedrine [1] 11
189 ADRA1A [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00255 Carvedilol [5] 6, 57, 86, 113, 210
190 ADRA1A [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00454 Olanzapine [2] 2, 8
191 ADRA1A [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00485 Pseudoephedrine [1] 17
192 ADRA1A [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00511 Phenylephrine [1] 22
193 ADRA1A [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00608 Doxazosin [2] 57, 67
194 ADRA1A [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00610 Terazosin [1] 6
195 ADRA1A [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00636 Amiodarone [2] 28, 127
196 ADRA1A [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00680 Methylergometrine [3] 118, 280, 288
197 ADRA1A [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00996 Epinephrine [3] 46, 70, 96
198 ADRA1A [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D01277 Droxidopa [5] 5, 6, 17, 169, 170
199 ADRA1A [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D01307 Midodrine [3] 6, 17, 58
200 ADRA1A [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D01692 Alfuzosin [1] 13
201 ADRA1A [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D01965 Silodosin [2] 6, 13
202 ADRA1A [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D02149 Epinephrine [3] 46, 70, 96
203 ADRA1A [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D02268 Ergoloid mesylate [2] 6, 206
204 ADRA1A [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D02349 Dipivefrin [1] 6
205 ADRA1A [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D02910 Amiodarone [2] 28, 127
206 ADRA1A [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D03415 Carvedilol [5] 6, 57, 86, 113, 210
207 ADRA1A [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D05206 Norepinephrine [1] 22
208 ADRA1A [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D05648 Pseudoephedrine [1] 17
209 ADRA1A [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D05649 Pseudoephedrine [1] 17
210 ADRA1A [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D06623 Olanzapine [2] 2, 8
211 ADRA1A [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D07124 Alfuzosin [1] 13
212 ADRA1A [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D07874 Doxazosin [2] 57, 67
213 ADRA1A [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08064 Ifenprodil [1] 85
214 ADRA1A [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08207 Methylergometrine [3] 118, 280, 288
215 ADRA1A [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08220 Midodrine [3] 6, 17, 58
216 ADRA1A [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08365 Phenylephrine [1] 22
217 ADRA1A [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08449 Pseudoephedrine [1] 17
218 ADRA1A [5] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08569 Terazosin [1] 6
219 ADRB1 [10] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00076 Norepinephrine [1] 22
220 ADRB1 [10] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00095 Epinephrine [3] 46, 70, 96
221 ADRB1 [10] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00124 Ephedrine [1] 11
222 ADRB1 [10] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00235 Atenolol [1] 167
223 ADRB1 [10] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00255 Carvedilol [5] 6, 57, 86, 113, 210
224 ADRB1 [10] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00378 Timolol [2] 157, 227
225 ADRB1 [10] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00432 Nadolol [1] 6
226 ADRB1 [10] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00483 Propranolol [7] 6, 158, 167, 215, 227, 278, 296
227 ADRB1 [10] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00485 Pseudoephedrine [1] 17
228 ADRB1 [10] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00601 Metoprolol [6] 17, 57, 58, 113, 193, 226
229 ADRB1 [10] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00603 Timolol [2] 157, 227
230 ADRB1 [10] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00632 Dobutamine [3] 57, 58, 215
231 ADRB1 [10] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00634 Bisoprolol [3] 67, 86, 113
232 ADRB1 [10] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00636 Amiodarone [2] 28, 127
233 ADRB1 [10] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00644 Esmolol [1] 58
234 ADRB1 [10] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00996 Epinephrine [3] 46, 70, 96
235 ADRB1 [10] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D01277 Droxidopa [5] 5, 6, 17, 169, 170
236 ADRB1 [10] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D02149 Epinephrine [3] 46, 70, 96
237 ADRB1 [10] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D02342 Bisoprolol [3] 67, 86, 113
238 ADRB1 [10] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D02349 Dipivefrin [1] 6
239 ADRB1 [10] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D02358 Metoprolol [6] 17, 57, 58, 113, 193, 226
240 ADRB1 [10] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D02910 Amiodarone [2] 28, 127
241 ADRB1 [10] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D03415 Carvedilol [5] 6, 57, 86, 113, 210
242 ADRB1 [10] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D03879 Dobutamine [3] 57, 58, 215
243 ADRB1 [10] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D03880 Dobutamine [3] 57, 58, 215
244 ADRB1 [10] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D03881 Dobutamine [3] 57, 58, 215
245 ADRB1 [10] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D05011 Metoprolol [6] 17, 57, 58, 113, 193, 226
246 ADRB1 [10] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D05127 Nebivolol [4] 17, 85, 113, 167
247 ADRB1 [10] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D05206 Norepinephrine [1] 22
248 ADRB1 [10] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D05648 Pseudoephedrine [1] 17
249 ADRB1 [10] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D05649 Pseudoephedrine [1] 17
250 ADRB1 [10] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D07660 Celiprolol [1] 168
251 ADRB1 [10] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D07916 Esmolol [1] 58
252 ADRB1 [10] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D08443 Propranolol [7] 6, 158, 167, 215, 227, 278, 296
253 ADRB1 [10] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D08449 Pseudoephedrine [1] 17
254 ADRB1 [10] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D08600 Timolol [2] 157, 227
255 ADRB2 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00076 Norepinephrine [1] 22
256 ADRB2 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00095 Epinephrine [3] 46, 70, 96
257 ADRB2 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00124 Ephedrine [1] 11
258 ADRB2 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00255 Carvedilol [5] 6, 57, 86, 113, 210
259 ADRB2 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00378 Timolol [2] 157, 227
260 ADRB2 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00432 Nadolol [1] 6
261 ADRB2 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00483 Propranolol [7] 6, 158, 167, 215, 227, 278, 296
262 ADRB2 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00485 Pseudoephedrine [1] 17
263 ADRB2 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00603 Timolol [2] 157, 227
264 ADRB2 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00687 Salmeterol [1] 299
265 ADRB2 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00688 Terbutaline [1] 118
266 ADRB2 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00996 Epinephrine [3] 46, 70, 96
267 ADRB2 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D01277 Droxidopa [5] 5, 6, 17, 169, 170
268 ADRB2 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D01373 Formoterol [3] 85, 228, 299
269 ADRB2 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D02147 Salbutamol [14] 3, 11, 12, 13, 49, 85, 86, 89, 111, 113, 228, 231, 256, 299
270 ADRB2 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D02149 Epinephrine [3] 46, 70, 96
271 ADRB2 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D02151 Tulobuterol [1] 6
272 ADRB2 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D02349 Dipivefrin [1] 6
273 ADRB2 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D03415 Carvedilol [5] 6, 57, 86, 113, 210
274 ADRB2 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D05206 Norepinephrine [1] 22
275 ADRB2 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D05277 Formoterol [3] 85, 228, 299
276 ADRB2 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D05648 Pseudoephedrine [1] 17
277 ADRB2 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D05649 Pseudoephedrine [1] 17
278 ADRB2 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D05792 Salmeterol [1] 299
279 ADRB2 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D07713 Clenbuterol [5] 1, 2, 6, 13, 256
280 ADRB2 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D07990 Formoterol [3] 85, 228, 299
281 ADRB2 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D08092 Isoxsuprine [1] 13
282 ADRB2 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D08124 Levosalbutamol [1] 49
283 ADRB2 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D08443 Propranolol [7] 6, 158, 167, 215, 227, 278, 296
284 ADRB2 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D08449 Pseudoephedrine [1] 17
285 ADRB2 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D08570 Terbutaline [1] 118
286 ADRB2 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D08600 Timolol [2] 157, 227
287 ADRB3 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00076 Norepinephrine [1] 22
288 ADRB3 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00095 Epinephrine [3] 46, 70, 96
289 ADRB3 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00124 Ephedrine [1] 11
290 ADRB3 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00483 Propranolol [7] 6, 158, 167, 215, 227, 278, 296
291 ADRB3 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00485 Pseudoephedrine [1] 17
292 ADRB3 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00996 Epinephrine [3] 46, 70, 96
293 ADRB3 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D01277 Droxidopa [5] 5, 6, 17, 169, 170
294 ADRB3 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D02149 Epinephrine [3] 46, 70, 96
295 ADRB3 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D02349 Dipivefrin [1] 6
296 ADRB3 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D05206 Norepinephrine [1] 22
297 ADRB3 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D05648 Pseudoephedrine [1] 17
298 ADRB3 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D05649 Pseudoephedrine [1] 17
299 ADRB3 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D08443 Propranolol [7] 6, 158, 167, 215, 227, 278, 296
300 ADRB3 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D08449 Pseudoephedrine [1] 17
301 ADRB3 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D09535 Mirabegron [4] 6, 13, 53, 226
302 DRD1 [8] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Morphine addiction D00059 Levodopa [8] 2, 4, 6, 17, 90, 140, 164, 201
303 DRD1 [8] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Morphine addiction D00502 Pergolide [1] 6
304 DRD1 [8] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Morphine addiction D00633 Dopamine [4] 6, 7, 74, 299
305 DRD1 [8] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Morphine addiction D01044 Flupentixol [1] 97
306 DRD1 [8] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Morphine addiction D02004 Apomorphine [3] 5, 6, 7
307 DRD1 [8] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Morphine addiction D07460 Apomorphine [3] 5, 6, 7
308 DRD1 [8] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Morphine addiction D07870 Dopamine [4] 6, 7, 74, 299
309 DRD1 [8] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Morphine addiction D08339 Pergolide [1] 6
310 DRD1 [8] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Morphine addiction D09886 Dexpramipexole [1] 2
311 DRD1 [8] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Morphine addiction D11431 Tavapadon [1] 6
312 DRD1 [8] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Morphine addiction D11839 Foslevodopa [1] 6
313 DRD5 [4] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Dopaminergic synapse D00059 Levodopa [8] 2, 4, 6, 17, 90, 140, 164, 201
314 DRD5 [4] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Dopaminergic synapse D00633 Dopamine [4] 6, 7, 74, 299
315 DRD5 [4] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Dopaminergic synapse D07870 Dopamine [4] 6, 7, 74, 299
316 DRD5 [4] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Dopaminergic synapse D09886 Dexpramipexole [1] 2
317 DRD5 [4] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Dopaminergic synapse D11431 Tavapadon [1] 6
318 DRD5 [4] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Dopaminergic synapse D11839 Foslevodopa [1] 6
319 AGTR1 [12] Calcium signaling pathway, cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin-angiotensin system, Renin secretion, Cortisol synthesis and secretion, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy D00150 Angiotensin II [7] 17, 19, 46, 66, 86, 222, 224
320 AGTR1 [12] Calcium signaling pathway, cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin-angiotensin system, Renin secretion, Cortisol synthesis and secretion, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy D00357 Losartan [18] 17, 19, 36, 46, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299
321 AGTR1 [12] Calcium signaling pathway, cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin-angiotensin system, Renin secretion, Cortisol synthesis and secretion, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy D00400 Valsartan [7] 57, 58, 66, 75, 218, 222, 224
322 AGTR1 [12] Calcium signaling pathway, cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin-angiotensin system, Renin secretion, Cortisol synthesis and secretion, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy D00522 Candesartan cilexetil [1] 67
323 AGTR1 [12] Calcium signaling pathway, cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin-angiotensin system, Renin secretion, Cortisol synthesis and secretion, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy D00522 Candesartan [2] 58, 67
324 AGTR1 [12] Calcium signaling pathway, cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin-angiotensin system, Renin secretion, Cortisol synthesis and secretion, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy D00523 Irbesartan [4] 66, 167, 168, 222
325 AGTR1 [12] Calcium signaling pathway, cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin-angiotensin system, Renin secretion, Cortisol synthesis and secretion, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy D00626 Candesartan cilexetil [1] 67
326 AGTR1 [12] Calcium signaling pathway, cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin-angiotensin system, Renin secretion, Cortisol synthesis and secretion, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy D00627 Telmisartan [2] 66, 67
327 AGTR1 [12] Calcium signaling pathway, cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin-angiotensin system, Renin secretion, Cortisol synthesis and secretion, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy D02014 Angiotensin II [7] 17, 19, 46, 66, 86, 222, 224
328 AGTR1 [12] Calcium signaling pathway, cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin-angiotensin system, Renin secretion, Cortisol synthesis and secretion, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy D08146 Losartan [18] 17, 19, 36, 46, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299
329 AGTR1 [12] Calcium signaling pathway, cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin-angiotensin system, Renin secretion, Cortisol synthesis and secretion, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy D11776 Sparsentan [3] 66, 218, 222
330 EDNRA [7] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin secretion, Pathways in cancer D01227 Bosentan [11] 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212
331 EDNRA [7] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin secretion, Pathways in cancer D07077 Ambrisentan [7] 51, 84, 85, 86, 88, 210, 211
332 EDNRA [7] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin secretion, Pathways in cancer D07171 Sitaxentan [1] 86
333 EDNRA [7] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin secretion, Pathways in cancer D07538 Bosentan [11] 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212
334 EDNRA [7] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin secretion, Pathways in cancer D07741 Zibotentan [1] 51
335 EDNRA [7] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin secretion, Pathways in cancer D10135 Macitentan [5] 51, 85, 86, 88, 210
336 EDNRA [7] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin secretion, Pathways in cancer D11776 Sparsentan [3] 66, 218, 222
337 EDNRB [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Melanogenesis, Relaxin signaling pathway, Pathways in cancer D01227 Bosentan [11] 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212
338 EDNRB [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Melanogenesis, Relaxin signaling pathway, Pathways in cancer D07538 Bosentan [11] 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212
339 EDNRB [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Melanogenesis, Relaxin signaling pathway, Pathways in cancer D10135 Macitentan [5] 51, 85, 86, 88, 210
340 EGFR [45] EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Phospholipase D signaling pathway, Endocytosis, PI3K-Akt signaling pathway, Focal adhesion, Gap junction, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, GnRH signaling pathway, Estrogen signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Cushing syndrome, Epithelial cell signaling in Helicobacter pylori infection, Shigellosis, Hepatitis C, Human cytomegalovirus infection, Human papillomavirus infection, Coronavirus disease - COVID-19, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Colorectal cancer, Pancreatic cancer, Endometrial cancer, Glioma, Prostate cancer, Melanoma, Non-small cell lung cancer, Hepatocellular carcinoma, Gastric cancer, Central carbon metabolism in cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D01977 Gefitinib [1] 75
341 EGFR [45] EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Phospholipase D signaling pathway, Endocytosis, PI3K-Akt signaling pathway, Focal adhesion, Gap junction, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, GnRH signaling pathway, Estrogen signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Cushing syndrome, Epithelial cell signaling in Helicobacter pylori infection, Shigellosis, Hepatitis C, Human cytomegalovirus infection, Human papillomavirus infection, Coronavirus disease - COVID-19, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Colorectal cancer, Pancreatic cancer, Endometrial cancer, Glioma, Prostate cancer, Melanoma, Non-small cell lung cancer, Hepatocellular carcinoma, Gastric cancer, Central carbon metabolism in cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D03455 Cetuximab [5] 34, 51, 86, 89, 331
342 EGFR [45] EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Phospholipase D signaling pathway, Endocytosis, PI3K-Akt signaling pathway, Focal adhesion, Gap junction, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, GnRH signaling pathway, Estrogen signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Cushing syndrome, Epithelial cell signaling in Helicobacter pylori infection, Shigellosis, Hepatitis C, Human cytomegalovirus infection, Human papillomavirus infection, Coronavirus disease - COVID-19, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Colorectal cancer, Pancreatic cancer, Endometrial cancer, Glioma, Prostate cancer, Melanoma, Non-small cell lung cancer, Hepatocellular carcinoma, Gastric cancer, Central carbon metabolism in cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D04023 Erlotinib [1] 94
343 EGFR [45] EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Phospholipase D signaling pathway, Endocytosis, PI3K-Akt signaling pathway, Focal adhesion, Gap junction, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, GnRH signaling pathway, Estrogen signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Cushing syndrome, Epithelial cell signaling in Helicobacter pylori infection, Shigellosis, Hepatitis C, Human cytomegalovirus infection, Human papillomavirus infection, Coronavirus disease - COVID-19, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Colorectal cancer, Pancreatic cancer, Endometrial cancer, Glioma, Prostate cancer, Melanoma, Non-small cell lung cancer, Hepatocellular carcinoma, Gastric cancer, Central carbon metabolism in cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D04024 Lapatinib [3] 34, 74, 75
344 EGFR [45] EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Phospholipase D signaling pathway, Endocytosis, PI3K-Akt signaling pathway, Focal adhesion, Gap junction, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, GnRH signaling pathway, Estrogen signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Cushing syndrome, Epithelial cell signaling in Helicobacter pylori infection, Shigellosis, Hepatitis C, Human cytomegalovirus infection, Human papillomavirus infection, Coronavirus disease - COVID-19, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Colorectal cancer, Pancreatic cancer, Endometrial cancer, Glioma, Prostate cancer, Melanoma, Non-small cell lung cancer, Hepatocellular carcinoma, Gastric cancer, Central carbon metabolism in cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D07907 Erlotinib [1] 94
345 EGFR [45] EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Phospholipase D signaling pathway, Endocytosis, PI3K-Akt signaling pathway, Focal adhesion, Gap junction, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, GnRH signaling pathway, Estrogen signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Cushing syndrome, Epithelial cell signaling in Helicobacter pylori infection, Shigellosis, Hepatitis C, Human cytomegalovirus infection, Human papillomavirus infection, Coronavirus disease - COVID-19, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Colorectal cancer, Pancreatic cancer, Endometrial cancer, Glioma, Prostate cancer, Melanoma, Non-small cell lung cancer, Hepatocellular carcinoma, Gastric cancer, Central carbon metabolism in cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D08108 Lapatinib [3] 34, 74, 75
346 EGFR [45] EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Phospholipase D signaling pathway, Endocytosis, PI3K-Akt signaling pathway, Focal adhesion, Gap junction, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, GnRH signaling pathway, Estrogen signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Cushing syndrome, Epithelial cell signaling in Helicobacter pylori infection, Shigellosis, Hepatitis C, Human cytomegalovirus infection, Human papillomavirus infection, Coronavirus disease - COVID-19, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Colorectal cancer, Pancreatic cancer, Endometrial cancer, Glioma, Prostate cancer, Melanoma, Non-small cell lung cancer, Hepatocellular carcinoma, Gastric cancer, Central carbon metabolism in cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D11251 Icotinib [1] 34
347 EGFR [45] EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Phospholipase D signaling pathway, Endocytosis, PI3K-Akt signaling pathway, Focal adhesion, Gap junction, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, GnRH signaling pathway, Estrogen signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Cushing syndrome, Epithelial cell signaling in Helicobacter pylori infection, Shigellosis, Hepatitis C, Human cytomegalovirus infection, Human papillomavirus infection, Coronavirus disease - COVID-19, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Colorectal cancer, Pancreatic cancer, Endometrial cancer, Glioma, Prostate cancer, Melanoma, Non-small cell lung cancer, Hepatocellular carcinoma, Gastric cancer, Central carbon metabolism in cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D11772 Tesevatinib [1] 67
348 ERBB2 [19] EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Platinum drug resistance, MAPK signaling pathway, ErbB signaling pathway, Calcium signaling pathway, HIF-1 signaling pathway, PI3K-Akt signaling pathway, Focal adhesion, Tight junction, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Pancreatic cancer, Endometrial cancer, Prostate cancer, Non-small cell lung cancer, Gastric cancer, Central carbon metabolism in cancer D04024 Lapatinib [3] 34, 74, 75
349 ERBB2 [19] EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Platinum drug resistance, MAPK signaling pathway, ErbB signaling pathway, Calcium signaling pathway, HIF-1 signaling pathway, PI3K-Akt signaling pathway, Focal adhesion, Tight junction, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Pancreatic cancer, Endometrial cancer, Prostate cancer, Non-small cell lung cancer, Gastric cancer, Central carbon metabolism in cancer D08108 Lapatinib [3] 34, 74, 75
350 ERBB2 [19] EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Platinum drug resistance, MAPK signaling pathway, ErbB signaling pathway, Calcium signaling pathway, HIF-1 signaling pathway, PI3K-Akt signaling pathway, Focal adhesion, Tight junction, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Pancreatic cancer, Endometrial cancer, Prostate cancer, Non-small cell lung cancer, Gastric cancer, Central carbon metabolism in cancer D11772 Tesevatinib [1] 67
351 FGFR1 [14] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, PI3K-Akt signaling pathway, Signaling pathways regulating pluripotency of stem cells, Thermogenesis, Regulation of actin cytoskeleton, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Proteoglycans in cancer, Prostate cancer, Melanoma, Central carbon metabolism in cancer D10481 Nintedanib [5] 51, 85, 89, 227, 228
352 FGFR1 [14] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, PI3K-Akt signaling pathway, Signaling pathways regulating pluripotency of stem cells, Thermogenesis, Regulation of actin cytoskeleton, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Proteoglycans in cancer, Prostate cancer, Melanoma, Central carbon metabolism in cancer D11589 Infigratinib [1] 276
353 FGFR3 [12] EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, Endocytosis, PI3K-Akt signaling pathway, Signaling pathways regulating pluripotency of stem cells, Regulation of actin cytoskeleton, Pathways in cancer, MicroRNAs in cancer, Central carbon metabolism in cancer D10481 Nintedanib [5] 51, 85, 89, 227, 228
354 FGFR3 [12] EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, Endocytosis, PI3K-Akt signaling pathway, Signaling pathways regulating pluripotency of stem cells, Regulation of actin cytoskeleton, Pathways in cancer, MicroRNAs in cancer, Central carbon metabolism in cancer D11589 Infigratinib [1] 276
355 FGFR2 [13] EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, Endocytosis, PI3K-Akt signaling pathway, Signaling pathways regulating pluripotency of stem cells, Regulation of actin cytoskeleton, Pathways in cancer, Prostate cancer, Gastric cancer, Central carbon metabolism in cancer D05338 Palifermin [5] 13, 36, 38, 39, 65
356 FGFR2 [13] EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, Endocytosis, PI3K-Akt signaling pathway, Signaling pathways regulating pluripotency of stem cells, Regulation of actin cytoskeleton, Pathways in cancer, Prostate cancer, Gastric cancer, Central carbon metabolism in cancer D10481 Nintedanib [5] 51, 85, 89, 227, 228
357 FGFR2 [13] EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, Endocytosis, PI3K-Akt signaling pathway, Signaling pathways regulating pluripotency of stem cells, Regulation of actin cytoskeleton, Pathways in cancer, Prostate cancer, Gastric cancer, Central carbon metabolism in cancer D11589 Infigratinib [1] 276
358 FLT1 [9] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, HIF-1 signaling pathway, PI3K-Akt signaling pathway, Focal adhesion, Transcriptional misregulation in cancer, Rheumatoid arthritis D03218 Axitinib [1] 34
359 FLT1 [9] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, HIF-1 signaling pathway, PI3K-Akt signaling pathway, Focal adhesion, Transcriptional misregulation in cancer, Rheumatoid arthritis D06402 Sunitinib [2] 28, 34
360 FLT1 [9] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, HIF-1 signaling pathway, PI3K-Akt signaling pathway, Focal adhesion, Transcriptional misregulation in cancer, Rheumatoid arthritis D08552 Sunitinib [2] 28, 34
361 FLT1 [9] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, HIF-1 signaling pathway, PI3K-Akt signaling pathway, Focal adhesion, Transcriptional misregulation in cancer, Rheumatoid arthritis D08881 Cediranib [1] 34
362 FLT1 [9] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, HIF-1 signaling pathway, PI3K-Akt signaling pathway, Focal adhesion, Transcriptional misregulation in cancer, Rheumatoid arthritis D10481 Nintedanib [5] 51, 85, 89, 227, 228
363 FLT4 [7] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, PI3K-Akt signaling pathway, Focal adhesion, Pathways in cancer D03218 Axitinib [1] 34
364 FLT4 [7] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, PI3K-Akt signaling pathway, Focal adhesion, Pathways in cancer D06272 Sorafenib [2] 34, 86
365 FLT4 [7] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, PI3K-Akt signaling pathway, Focal adhesion, Pathways in cancer D06402 Sunitinib [2] 28, 34
366 FLT4 [7] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, PI3K-Akt signaling pathway, Focal adhesion, Pathways in cancer D08524 Sorafenib [2] 34, 86
367 FLT4 [7] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, PI3K-Akt signaling pathway, Focal adhesion, Pathways in cancer D08552 Sunitinib [2] 28, 34
368 FLT4 [7] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, PI3K-Akt signaling pathway, Focal adhesion, Pathways in cancer D08881 Cediranib [1] 34
369 FLT4 [7] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, PI3K-Akt signaling pathway, Focal adhesion, Pathways in cancer D10481 Nintedanib [5] 51, 85, 89, 227, 228
370 FLT4 [7] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, PI3K-Akt signaling pathway, Focal adhesion, Pathways in cancer D11772 Tesevatinib [1] 67
371 GRIN1 [14] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D00711 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
372 GRIN1 [14] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
373 GRIN1 [14] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D00777 Amantadine [4] 6, 8, 13, 127
374 GRIN1 [14] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D00848 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
375 GRIN1 [14] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D02780 Acamprosate [2] 6, 206
376 GRIN1 [14] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D03742 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
377 GRIN1 [14] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D03744 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
378 GRIN1 [14] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D04905 Memantine [7] 2, 6, 8, 13, 49, 127, 205
379 GRIN1 [14] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D07058 Acamprosate [2] 6, 206
380 GRIN1 [14] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D07283 Esketamine [3] 2, 4, 70
381 GRIN1 [14] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D07441 Amantadine [4] 6, 8, 13, 127
382 GRIN1 [14] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D08098 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
383 GRIN1 [14] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D08174 Memantine [7] 2, 6, 8, 13, 49, 127, 205
384 GRIN1 [14] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D09917 Latrepirdine [1] 8
385 GRIN2A [15] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction, Systemic lupus erythematosus D00711 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
386 GRIN2A [15] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction, Systemic lupus erythematosus D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
387 GRIN2A [15] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction, Systemic lupus erythematosus D00777 Amantadine [4] 6, 8, 13, 127
388 GRIN2A [15] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction, Systemic lupus erythematosus D00848 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
389 GRIN2A [15] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction, Systemic lupus erythematosus D02780 Acamprosate [2] 6, 206
390 GRIN2A [15] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction, Systemic lupus erythematosus D03742 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
391 GRIN2A [15] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction, Systemic lupus erythematosus D03744 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
392 GRIN2A [15] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction, Systemic lupus erythematosus D04905 Memantine [7] 2, 6, 8, 13, 49, 127, 205
393 GRIN2A [15] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction, Systemic lupus erythematosus D07058 Acamprosate [2] 6, 206
394 GRIN2A [15] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction, Systemic lupus erythematosus D07283 Esketamine [3] 2, 4, 70
395 GRIN2A [15] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction, Systemic lupus erythematosus D07441 Amantadine [4] 6, 8, 13, 127
396 GRIN2A [15] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction, Systemic lupus erythematosus D08098 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
397 GRIN2A [15] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction, Systemic lupus erythematosus D08174 Memantine [7] 2, 6, 8, 13, 49, 127, 205
398 GRIN2A [15] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction, Systemic lupus erythematosus D09917 Latrepirdine [1] 8
399 GRIN2C [11] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D00711 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
400 GRIN2C [11] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
401 GRIN2C [11] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D00777 Amantadine [4] 6, 8, 13, 127
402 GRIN2C [11] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D00848 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
403 GRIN2C [11] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D02780 Acamprosate [2] 6, 206
404 GRIN2C [11] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D03742 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
405 GRIN2C [11] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D03744 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
406 GRIN2C [11] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D04905 Memantine [7] 2, 6, 8, 13, 49, 127, 205
407 GRIN2C [11] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D07058 Acamprosate [2] 6, 206
408 GRIN2C [11] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D07283 Esketamine [3] 2, 4, 70
409 GRIN2C [11] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D07441 Amantadine [4] 6, 8, 13, 127
410 GRIN2C [11] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D08098 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
411 GRIN2C [11] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D08174 Memantine [7] 2, 6, 8, 13, 49, 127, 205
412 GRIN2C [11] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D09917 Latrepirdine [1] 8
413 GRIN2D [11] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D00711 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
414 GRIN2D [11] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
415 GRIN2D [11] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D00777 Amantadine [4] 6, 8, 13, 127
416 GRIN2D [11] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D00848 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
417 GRIN2D [11] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D02780 Acamprosate [2] 6, 206
418 GRIN2D [11] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D03742 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
419 GRIN2D [11] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D03744 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
420 GRIN2D [11] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D04905 Memantine [7] 2, 6, 8, 13, 49, 127, 205
421 GRIN2D [11] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D07058 Acamprosate [2] 6, 206
422 GRIN2D [11] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D07283 Esketamine [3] 2, 4, 70
423 GRIN2D [11] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D07441 Amantadine [4] 6, 8, 13, 127
424 GRIN2D [11] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D08098 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
425 GRIN2D [11] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D08174 Memantine [7] 2, 6, 8, 13, 49, 127, 205
426 GRIN2D [11] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D09917 Latrepirdine [1] 8
427 HRH1 [3] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D00270 Chlorpromazine [1] 254
428 HRH1 [3] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D00300 Diphenhydramine [10] 11, 13, 49, 51, 70, 86, 96, 222, 256, 300
429 HRH1 [3] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D00364 Loratadine [4] 13, 46, 89, 98
430 HRH1 [3] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D00454 Olanzapine [2] 2, 8
431 HRH1 [3] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D00480 Promethazine [1] 96
432 HRH1 [3] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D00494 Promethazine [1] 96
433 HRH1 [3] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D00664 Cetirizine [4] 13, 28, 35, 300
434 HRH1 [3] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D00665 Chlorpheniramine [1] 14
435 HRH1 [3] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D00666 Clemastine [1] 13
436 HRH1 [3] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D00668 Chlorpheniramine [1] 14
437 HRH1 [3] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D00669 Diphenhydramine [10] 11, 13, 49, 51, 70, 86, 96, 222, 256, 300
438 HRH1 [3] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D00671 Fexofenadine [2] 13, 46
439 HRH1 [3] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D00789 Chlorpromazine [1] 254
440 HRH1 [3] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D00814 Doxepin [1] 6
441 HRH1 [3] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D01172 Diphenylpyraline [1] 98
442 HRH1 [3] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D01242 Promethazine [1] 96
443 HRH1 [3] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D01627 Diphenylpyraline [1] 98
444 HRH1 [3] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D02419 Diphenhydramine [10] 11, 13, 49, 51, 70, 86, 96, 222, 256, 300
445 HRH1 [3] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D03274 Chlorpromazine [1] 254
446 HRH1 [3] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D03285 Diphenhydramine [10] 11, 13, 49, 51, 70, 86, 96, 222, 256, 300
447 HRH1 [3] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D03290 Promethazine [1] 96
448 HRH1 [3] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D03360 Diphenhydramine [10] 11, 13, 49, 51, 70, 86, 96, 222, 256, 300
449 HRH1 [3] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D03535 Clemastine [1] 13
450 HRH1 [3] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D03693 Desloratadine [1] 13
451 HRH1 [3] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D03854 Diphenhydramine [10] 11, 13, 49, 51, 70, 86, 96, 222, 256, 300
452 HRH1 [3] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D04034 Chlorpromazine [1] 254
453 HRH1 [3] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D06623 Olanzapine [2] 2, 8
454 HRH1 [3] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D07398 Chlorpheniramine [1] 14
455 HRH1 [3] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D07402 Levocetirizine [1] 61
456 HRH1 [3] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D07407 Rupatadine [1] 46
457 HRH1 [3] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D07662 Cetirizine [4] 13, 28, 35, 300
458 HRH1 [3] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D07803 Chlorpheniramine [1] 14
459 HRH1 [3] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D07803 Dexchlorpheniramine [2] 13, 49
460 HRH1 [3] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D07862 Diphenylpyraline [1] 98
461 HRH1 [3] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D07875 Doxepin [1] 6
462 HRH1 [3] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D07958 Fexofenadine [2] 13, 46
463 HRH1 [3] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D08040 Histamine [1] 13
464 HRH2 [3] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gastric acid secretion D00295 Cimetidine [2] 2, 254
465 HRH2 [3] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gastric acid secretion D00318 Famotidine [7] 6, 46, 61, 86, 98, 107, 300
466 HRH2 [3] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gastric acid secretion D00422 Ranitidine [2] 13, 65
467 HRH2 [3] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gastric acid secretion D00673 Ranitidine [2] 13, 65
468 HRH2 [3] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gastric acid secretion D03503 Cimetidine [2] 2, 254
469 HRH2 [3] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gastric acid secretion D08040 Histamine [1] 13
470 HTR2A [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D00270 Chlorpromazine [1] 254
471 HTR2A [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D00274 Cisapride [1] 13
472 HTR2A [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D00283 Clozapine [1] 6
473 HTR2A [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D00426 Risperidone [5] 8, 156, 179, 187, 206
474 HTR2A [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D00454 Olanzapine [2] 2, 8
475 HTR2A [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D00458 Quetiapine [2] 6, 13
476 HTR2A [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D00789 Chlorpromazine [1] 254
477 HTR2A [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D00820 Trazodone [1] 2
478 HTR2A [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D01164 Aripiprazole [2] 6, 206
479 HTR2A [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D02092 Cisapride [1] 13
480 HTR2A [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D03274 Chlorpromazine [1] 254
481 HTR2A [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D04034 Chlorpromazine [1] 254
482 HTR2A [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D06623 Olanzapine [2] 2, 8
483 HTR2A [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D07945 Fenfluramine [4] 140, 144, 145, 149
484 HTR2A [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D08456 Quetiapine [2] 6, 13
485 HTR2A [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D08626 Trazodone [1] 2
486 HTR2A [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D09645 Nelotanserin [1] 6
487 HTR2A [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D09997 Cariprazine [1] 21
488 HTR2B [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D00270 Chlorpromazine [1] 254
489 HTR2B [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D00454 Olanzapine [2] 2, 8
490 HTR2B [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D00789 Chlorpromazine [1] 254
491 HTR2B [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D00820 Trazodone [1] 2
492 HTR2B [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D03274 Chlorpromazine [1] 254
493 HTR2B [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D04034 Chlorpromazine [1] 254
494 HTR2B [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D06623 Olanzapine [2] 2, 8
495 HTR2B [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D07945 Fenfluramine [4] 140, 144, 145, 149
496 HTR2B [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D08626 Trazodone [1] 2
497 HTR2C [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D00270 Chlorpromazine [1] 254
498 HTR2C [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D00283 Clozapine [1] 6
499 HTR2C [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D00454 Olanzapine [2] 2, 8
500 HTR2C [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D00789 Chlorpromazine [1] 254
501 HTR2C [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D00820 Trazodone [1] 2
502 HTR2C [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D02578 Agomelatine [1] 6
503 HTR2C [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D03274 Chlorpromazine [1] 254
504 HTR2C [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D04034 Chlorpromazine [1] 254
505 HTR2C [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D06623 Olanzapine [2] 2, 8
506 HTR2C [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D07945 Fenfluramine [4] 140, 144, 145, 149
507 HTR2C [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D08626 Trazodone [1] 2
508 HTR4 [4] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Serotonergic synapse D00274 Cisapride [1] 13
509 HTR4 [4] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Serotonergic synapse D02092 Cisapride [1] 13
510 HTR4 [4] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Serotonergic synapse D08236 Mosapride [1] 96
511 HTR4 [4] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Serotonergic synapse D09205 Prucalopride [3] 13, 51, 96
512 HTR4 [4] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Serotonergic synapse D09693 Velusetrag [1] 99
513 HTR6 [4] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Serotonergic synapse D00454 Olanzapine [2] 2, 8
514 HTR6 [4] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Serotonergic synapse D06623 Olanzapine [2] 2, 8
515 KDR [10] EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, PI3K-Akt signaling pathway, VEGF signaling pathway, Focal adhesion, Proteoglycans in cancer, Fluid shear stress and atherosclerosis D03218 Axitinib [1] 34
516 KDR [10] EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, PI3K-Akt signaling pathway, VEGF signaling pathway, Focal adhesion, Proteoglycans in cancer, Fluid shear stress and atherosclerosis D06272 Sorafenib [2] 34, 86
517 KDR [10] EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, PI3K-Akt signaling pathway, VEGF signaling pathway, Focal adhesion, Proteoglycans in cancer, Fluid shear stress and atherosclerosis D06402 Sunitinib [2] 28, 34
518 KDR [10] EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, PI3K-Akt signaling pathway, VEGF signaling pathway, Focal adhesion, Proteoglycans in cancer, Fluid shear stress and atherosclerosis D08524 Sorafenib [2] 34, 86
519 KDR [10] EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, PI3K-Akt signaling pathway, VEGF signaling pathway, Focal adhesion, Proteoglycans in cancer, Fluid shear stress and atherosclerosis D08552 Sunitinib [2] 28, 34
520 KDR [10] EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, PI3K-Akt signaling pathway, VEGF signaling pathway, Focal adhesion, Proteoglycans in cancer, Fluid shear stress and atherosclerosis D08881 Cediranib [1] 34
521 KDR [10] EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, PI3K-Akt signaling pathway, VEGF signaling pathway, Focal adhesion, Proteoglycans in cancer, Fluid shear stress and atherosclerosis D10062 Cabozantinib [1] 34
522 KDR [10] EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, PI3K-Akt signaling pathway, VEGF signaling pathway, Focal adhesion, Proteoglycans in cancer, Fluid shear stress and atherosclerosis D10481 Nintedanib [5] 51, 85, 89, 227, 228
523 KDR [10] EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, PI3K-Akt signaling pathway, VEGF signaling pathway, Focal adhesion, Proteoglycans in cancer, Fluid shear stress and atherosclerosis D11772 Tesevatinib [1] 67
524 MET [20] EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, PI3K-Akt signaling pathway, Focal adhesion, Epithelial cell signaling in Helicobacter pylori infection, Malaria, Pathways in cancer, Transcriptional misregulation in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - reactive oxygen species, Renal cell carcinoma, Melanoma, Non-small cell lung cancer, Hepatocellular carcinoma, Gastric cancer, Central carbon metabolism in cancer D10062 Cabozantinib [1] 34
525 NGF [8] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Neurotrophin signaling pathway, Inflammatory mediator regulation of TRP channels D09387 Tanezumab [2] 226, 298
526 OXTR [4] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Oxytocin signaling pathway D00089 Oxytocin [6] 6, 72, 127, 193, 206, 226
527 OXTR [4] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Oxytocin signaling pathway D03008 Atosiban [1] 118
528 OXTR [4] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Oxytocin signaling pathway D07229 Carbetocin [1] 193
529 P2RX3 [3] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Taste transduction D11349 Gefapixant [2] 85, 226
530 PDE1A [7] Purine metabolism, Metabolic pathways, Calcium signaling pathway, Olfactory transduction, Taste transduction, Renin secretion, Morphine addiction D00227 Aminophylline [1] 63
531 PDE1A [7] Purine metabolism, Metabolic pathways, Calcium signaling pathway, Olfactory transduction, Taste transduction, Renin secretion, Morphine addiction D00371 Theophylline [2] 236, 299
532 PDE1A [7] Purine metabolism, Metabolic pathways, Calcium signaling pathway, Olfactory transduction, Taste transduction, Renin secretion, Morphine addiction D00718 Flavoxate [1] 226
533 PDE1A [7] Purine metabolism, Metabolic pathways, Calcium signaling pathway, Olfactory transduction, Taste transduction, Renin secretion, Morphine addiction D01712 Theophylline [2] 236, 299
534 PDE1A [7] Purine metabolism, Metabolic pathways, Calcium signaling pathway, Olfactory transduction, Taste transduction, Renin secretion, Morphine addiction D02017 Theophylline [2] 236, 299
535 PDE1A [7] Purine metabolism, Metabolic pathways, Calcium signaling pathway, Olfactory transduction, Taste transduction, Renin secretion, Morphine addiction D05429 Aminophylline [1] 63
536 PDE1A [7] Purine metabolism, Metabolic pathways, Calcium signaling pathway, Olfactory transduction, Taste transduction, Renin secretion, Morphine addiction D06103 Theophylline [2] 236, 299
537 PDE1A [7] Purine metabolism, Metabolic pathways, Calcium signaling pathway, Olfactory transduction, Taste transduction, Renin secretion, Morphine addiction D06104 Theophylline [2] 236, 299
538 PDE1A [7] Purine metabolism, Metabolic pathways, Calcium signaling pathway, Olfactory transduction, Taste transduction, Renin secretion, Morphine addiction D07546 Bucladesine [1] 246
539 PDE1A [7] Purine metabolism, Metabolic pathways, Calcium signaling pathway, Olfactory transduction, Taste transduction, Renin secretion, Morphine addiction D07961 Flavoxate [1] 226
540 PDE1C [7] Purine metabolism, Metabolic pathways, Calcium signaling pathway, Olfactory transduction, Taste transduction, Renin secretion, Morphine addiction D00227 Aminophylline [1] 63
541 PDE1C [7] Purine metabolism, Metabolic pathways, Calcium signaling pathway, Olfactory transduction, Taste transduction, Renin secretion, Morphine addiction D00371 Theophylline [2] 236, 299
542 PDE1C [7] Purine metabolism, Metabolic pathways, Calcium signaling pathway, Olfactory transduction, Taste transduction, Renin secretion, Morphine addiction D00718 Flavoxate [1] 226
543 PDE1C [7] Purine metabolism, Metabolic pathways, Calcium signaling pathway, Olfactory transduction, Taste transduction, Renin secretion, Morphine addiction D01712 Theophylline [2] 236, 299
544 PDE1C [7] Purine metabolism, Metabolic pathways, Calcium signaling pathway, Olfactory transduction, Taste transduction, Renin secretion, Morphine addiction D02017 Theophylline [2] 236, 299
545 PDE1C [7] Purine metabolism, Metabolic pathways, Calcium signaling pathway, Olfactory transduction, Taste transduction, Renin secretion, Morphine addiction D05429 Aminophylline [1] 63
546 PDE1C [7] Purine metabolism, Metabolic pathways, Calcium signaling pathway, Olfactory transduction, Taste transduction, Renin secretion, Morphine addiction D06103 Theophylline [2] 236, 299
547 PDE1C [7] Purine metabolism, Metabolic pathways, Calcium signaling pathway, Olfactory transduction, Taste transduction, Renin secretion, Morphine addiction D06104 Theophylline [2] 236, 299
548 PDE1C [7] Purine metabolism, Metabolic pathways, Calcium signaling pathway, Olfactory transduction, Taste transduction, Renin secretion, Morphine addiction D07546 Bucladesine [1] 246
549 PDE1C [7] Purine metabolism, Metabolic pathways, Calcium signaling pathway, Olfactory transduction, Taste transduction, Renin secretion, Morphine addiction D07961 Flavoxate [1] 226
550 PDE1B [7] Purine metabolism, Metabolic pathways, Calcium signaling pathway, Olfactory transduction, Taste transduction, Renin secretion, Morphine addiction D00227 Aminophylline [1] 63
551 PDE1B [7] Purine metabolism, Metabolic pathways, Calcium signaling pathway, Olfactory transduction, Taste transduction, Renin secretion, Morphine addiction D00371 Theophylline [2] 236, 299
552 PDE1B [7] Purine metabolism, Metabolic pathways, Calcium signaling pathway, Olfactory transduction, Taste transduction, Renin secretion, Morphine addiction D00528 Caffeine [9] 2, 6, 13, 21, 46, 78, 96, 97, 265
553 PDE1B [7] Purine metabolism, Metabolic pathways, Calcium signaling pathway, Olfactory transduction, Taste transduction, Renin secretion, Morphine addiction D00718 Flavoxate [1] 226
554 PDE1B [7] Purine metabolism, Metabolic pathways, Calcium signaling pathway, Olfactory transduction, Taste transduction, Renin secretion, Morphine addiction D01453 Caffeine [9] 2, 6, 13, 21, 46, 78, 96, 97, 265
555 PDE1B [7] Purine metabolism, Metabolic pathways, Calcium signaling pathway, Olfactory transduction, Taste transduction, Renin secretion, Morphine addiction D01712 Theophylline [2] 236, 299
556 PDE1B [7] Purine metabolism, Metabolic pathways, Calcium signaling pathway, Olfactory transduction, Taste transduction, Renin secretion, Morphine addiction D02017 Theophylline [2] 236, 299
557 PDE1B [7] Purine metabolism, Metabolic pathways, Calcium signaling pathway, Olfactory transduction, Taste transduction, Renin secretion, Morphine addiction D05429 Aminophylline [1] 63
558 PDE1B [7] Purine metabolism, Metabolic pathways, Calcium signaling pathway, Olfactory transduction, Taste transduction, Renin secretion, Morphine addiction D06103 Theophylline [2] 236, 299
559 PDE1B [7] Purine metabolism, Metabolic pathways, Calcium signaling pathway, Olfactory transduction, Taste transduction, Renin secretion, Morphine addiction D06104 Theophylline [2] 236, 299
560 PDE1B [7] Purine metabolism, Metabolic pathways, Calcium signaling pathway, Olfactory transduction, Taste transduction, Renin secretion, Morphine addiction D07546 Bucladesine [1] 246
561 PDE1B [7] Purine metabolism, Metabolic pathways, Calcium signaling pathway, Olfactory transduction, Taste transduction, Renin secretion, Morphine addiction D07961 Flavoxate [1] 226
562 PDGFRA [20] EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, Phospholipase D signaling pathway, Endocytosis, PI3K-Akt signaling pathway, Focal adhesion, Gap junction, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Human cytomegalovirus infection, Pathways in cancer, MicroRNAs in cancer, Glioma, Prostate cancer, Melanoma, Central carbon metabolism in cancer, Choline metabolism in cancer D01441 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162
563 PDGFRA [20] EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, Phospholipase D signaling pathway, Endocytosis, PI3K-Akt signaling pathway, Focal adhesion, Gap junction, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Human cytomegalovirus infection, Pathways in cancer, MicroRNAs in cancer, Glioma, Prostate cancer, Melanoma, Central carbon metabolism in cancer, Choline metabolism in cancer D06402 Sunitinib [2] 28, 34
564 PDGFRA [20] EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, Phospholipase D signaling pathway, Endocytosis, PI3K-Akt signaling pathway, Focal adhesion, Gap junction, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Human cytomegalovirus infection, Pathways in cancer, MicroRNAs in cancer, Glioma, Prostate cancer, Melanoma, Central carbon metabolism in cancer, Choline metabolism in cancer D08066 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162
565 PDGFRA [20] EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, Phospholipase D signaling pathway, Endocytosis, PI3K-Akt signaling pathway, Focal adhesion, Gap junction, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Human cytomegalovirus infection, Pathways in cancer, MicroRNAs in cancer, Glioma, Prostate cancer, Melanoma, Central carbon metabolism in cancer, Choline metabolism in cancer D08552 Sunitinib [2] 28, 34
566 PDGFRA [20] EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, Phospholipase D signaling pathway, Endocytosis, PI3K-Akt signaling pathway, Focal adhesion, Gap junction, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Human cytomegalovirus infection, Pathways in cancer, MicroRNAs in cancer, Glioma, Prostate cancer, Melanoma, Central carbon metabolism in cancer, Choline metabolism in cancer D08953 Nilotinib [5] 6, 8, 34, 51, 86
567 PDGFRA [20] EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, Phospholipase D signaling pathway, Endocytosis, PI3K-Akt signaling pathway, Focal adhesion, Gap junction, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Human cytomegalovirus infection, Pathways in cancer, MicroRNAs in cancer, Glioma, Prostate cancer, Melanoma, Central carbon metabolism in cancer, Choline metabolism in cancer D10481 Nintedanib [5] 51, 85, 89, 227, 228
568 PDGFRB [19] EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Focal adhesion, Gap junction, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Human papillomavirus infection, Pathways in cancer, MicroRNAs in cancer, Glioma, Prostate cancer, Melanoma, Central carbon metabolism in cancer, Choline metabolism in cancer D03658 Dasatinib [2] 51, 85
569 PDGFRB [19] EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Focal adhesion, Gap junction, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Human papillomavirus infection, Pathways in cancer, MicroRNAs in cancer, Glioma, Prostate cancer, Melanoma, Central carbon metabolism in cancer, Choline metabolism in cancer D06272 Sorafenib [2] 34, 86
570 PDGFRB [19] EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Focal adhesion, Gap junction, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Human papillomavirus infection, Pathways in cancer, MicroRNAs in cancer, Glioma, Prostate cancer, Melanoma, Central carbon metabolism in cancer, Choline metabolism in cancer D06402 Sunitinib [2] 28, 34
571 PDGFRB [19] EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Focal adhesion, Gap junction, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Human papillomavirus infection, Pathways in cancer, MicroRNAs in cancer, Glioma, Prostate cancer, Melanoma, Central carbon metabolism in cancer, Choline metabolism in cancer D06414 Dasatinib [2] 51, 85
572 PDGFRB [19] EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Focal adhesion, Gap junction, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Human papillomavirus infection, Pathways in cancer, MicroRNAs in cancer, Glioma, Prostate cancer, Melanoma, Central carbon metabolism in cancer, Choline metabolism in cancer D08524 Sorafenib [2] 34, 86
573 PDGFRB [19] EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Focal adhesion, Gap junction, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Human papillomavirus infection, Pathways in cancer, MicroRNAs in cancer, Glioma, Prostate cancer, Melanoma, Central carbon metabolism in cancer, Choline metabolism in cancer D08552 Sunitinib [2] 28, 34
574 PDGFRB [19] EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Focal adhesion, Gap junction, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Human papillomavirus infection, Pathways in cancer, MicroRNAs in cancer, Glioma, Prostate cancer, Melanoma, Central carbon metabolism in cancer, Choline metabolism in cancer D08953 Nilotinib [5] 6, 8, 34, 51, 86
575 PDGFRB [19] EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Focal adhesion, Gap junction, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Human papillomavirus infection, Pathways in cancer, MicroRNAs in cancer, Glioma, Prostate cancer, Melanoma, Central carbon metabolism in cancer, Choline metabolism in cancer D10481 Nintedanib [5] 51, 85, 89, 227, 228
576 AVPR1A [4] Calcium signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction D00101 Vasopressin [1] 210
577 AVPR1A [4] Calcium signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction D01236 Conivaptan [1] 86
578 AVPR1A [4] Calcium signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction D06672 Terlipressin [1] 299
579 AVPR1A [4] Calcium signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction D07748 Conivaptan [1] 86
580 PPP3CA [27] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00107 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
581 PPP3CA [27] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00184 Cyclosporine [44] 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326
582 PPP3CA [27] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D05480 Pimecrolimus [1] 160
583 PPP3CA [27] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D08556 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
584 PPP3CA [27] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D09033 Voclosporin [1] 222
585 PPP3CB [27] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00107 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
586 PPP3CB [27] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00184 Cyclosporine [44] 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326
587 PPP3CB [27] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D05480 Pimecrolimus [1] 160
588 PPP3CB [27] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D08556 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
589 PPP3CB [27] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D09033 Voclosporin [1] 222
590 PPP3CC [27] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00107 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
591 PPP3CC [27] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00184 Cyclosporine [44] 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326
592 PPP3CC [27] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D05480 Pimecrolimus [1] 160
593 PPP3CC [27] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D08556 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
594 PPP3CC [27] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D09033 Voclosporin [1] 222
595 PPP3R1 [26] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00107 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
596 PPP3R1 [26] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00184 Cyclosporine [44] 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326
597 PPP3R1 [26] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D05480 Pimecrolimus [1] 160
598 PPP3R1 [26] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D08556 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
599 PPP3R1 [26] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D09033 Voclosporin [1] 222
600 PPP3R2 [26] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00107 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
601 PPP3R2 [26] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00184 Cyclosporine [44] 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326
602 PPP3R2 [26] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D05480 Pimecrolimus [1] 160
603 PPP3R2 [26] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D08556 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
604 PPP3R2 [26] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D09033 Voclosporin [1] 222
605 AVPR1B [4] Calcium signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction D00101 Vasopressin [1] 210
606 AVPR1B [4] Calcium signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction D06672 Terlipressin [1] 299
607 PTAFR [3] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Staphylococcus aureus infection D07407 Rupatadine [1] 46
608 PTGER1 [4] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Human cytomegalovirus infection, Pathways in cancer D00180 Alprostadil [2] 51, 70
609 PTGER1 [4] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Human cytomegalovirus infection, Pathways in cancer D02705 Alprostadil [2] 51, 70
610 PTGER1 [4] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Human cytomegalovirus infection, Pathways in cancer D02722 Limaprost [1] 70
611 PTGER3 [6] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Human cytomegalovirus infection, Pathways in cancer D00419 Misoprostol [3] 46, 70, 271
612 PTGFR [3] Calcium signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction D06274 Tafluprost [1] 299
613 PTGFR [3] Calcium signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction D08661 Unoprostone [1] 90
614 RET [5] Calcium signaling pathway, Pathways in cancer, Thyroid cancer, Non-small cell lung cancer, Central carbon metabolism in cancer D06272 Sorafenib [2] 34, 86
615 RET [5] Calcium signaling pathway, Pathways in cancer, Thyroid cancer, Non-small cell lung cancer, Central carbon metabolism in cancer D06402 Sunitinib [2] 28, 34
616 RET [5] Calcium signaling pathway, Pathways in cancer, Thyroid cancer, Non-small cell lung cancer, Central carbon metabolism in cancer D08524 Sorafenib [2] 34, 86
617 RET [5] Calcium signaling pathway, Pathways in cancer, Thyroid cancer, Non-small cell lung cancer, Central carbon metabolism in cancer D08552 Sunitinib [2] 28, 34
618 TACR1 [2] Calcium signaling pathway, Neuroactive ligand-receptor interaction D09378 Serlopitant [1] 36
619 TBXA2R [3] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Platelet activation D01128 Ramatroban [1] 13
620 TBXA2R [3] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Platelet activation D01896 Cilostazol [3] 51, 70, 124
621 TBXA2R [3] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Platelet activation D04500 Ifetroban [3] 51, 86, 113
622 TNNC2 [1] Calcium signaling pathway D11363 Reldesemtiv [2] 2, 3
623 TRHR [2] Calcium signaling pathway, Neuroactive ligand-receptor interaction D00176 Protirelin [1] 80
624 VEGFA [22] EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, HIF-1 signaling pathway, PI3K-Akt signaling pathway, VEGF signaling pathway, Focal adhesion, Relaxin signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Renal cell carcinoma, Pancreatic cancer, Rheumatoid arthritis, Fluid shear stress and atherosclerosis D05697 Ranibizumab [4] 34, 166, 227, 301
625 VEGFA [22] EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, HIF-1 signaling pathway, PI3K-Akt signaling pathway, VEGF signaling pathway, Focal adhesion, Relaxin signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Renal cell carcinoma, Pancreatic cancer, Rheumatoid arthritis, Fluid shear stress and atherosclerosis D06409 Bevacizumab [9] 13, 34, 85, 86, 87, 89, 227, 280, 331
626 VEGFA [22] EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, HIF-1 signaling pathway, PI3K-Akt signaling pathway, VEGF signaling pathway, Focal adhesion, Relaxin signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Renal cell carcinoma, Pancreatic cancer, Rheumatoid arthritis, Fluid shear stress and atherosclerosis D09574 Aflibercept [2] 90, 166
627 VEGFB [8] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, PI3K-Akt signaling pathway, Focal adhesion, Relaxin signaling pathway, Pathways in cancer D09574 Aflibercept [2] 90, 166
628 CACNA1B [15] MAPK signaling pathway, Calcium signaling pathway, Synaptic vesicle cycle, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Type II diabetes mellitus, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Morphine addiction, Nicotine addiction, Chemical carcinogenesis - receptor activation D01173 Cilnidipine [1] 67
629 CACNA1C [29] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00349 Isradipine [1] 6
630 CACNA1C [29] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00437 Nifedipine [2] 50, 81
631 CACNA1C [29] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
632 CACNA1C [29] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00615 Amlodipine [4] 13, 51, 67, 298
633 CACNA1C [29] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00616 Diltiazem [3] 51, 58, 86
634 CACNA1C [29] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00617 Nicardipine [2] 70, 86
635 CACNA1C [29] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00619 Verapamil [3] 96, 140, 167
636 CACNA1C [29] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D01173 Cilnidipine [1] 67
637 CACNA1C [29] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D01908 Nilvadipine [1] 90
638 CACNA1C [29] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D02356 Verapamil [3] 96, 140, 167
639 CACNA1C [29] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D02914 Amlodipine [4] 13, 51, 67, 298
640 CACNA1C [29] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D03830 Diltiazem [3] 51, 58, 86
641 CACNA1C [29] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D05442 Perhexiline [2] 58, 272
642 CACNA1C [29] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D07450 Amlodipine [4] 13, 51, 67, 298
643 CACNA1C [29] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D07845 Diltiazem [3] 51, 58, 86
644 CACNA1C [29] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D08270 Nicardipine [2] 70, 86
645 CACNA1C [29] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D08340 Perhexiline [2] 58, 272
646 CACNA1C [29] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D08441 Propiverine [1] 226
647 CACNA1D [30] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cellular senescence, Cardiac muscle contraction, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Carbohydrate digestion and absorption, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00349 Isradipine [1] 6
648 CACNA1D [30] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cellular senescence, Cardiac muscle contraction, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Carbohydrate digestion and absorption, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00437 Nifedipine [2] 50, 81
649 CACNA1D [30] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cellular senescence, Cardiac muscle contraction, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Carbohydrate digestion and absorption, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
650 CACNA1D [30] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cellular senescence, Cardiac muscle contraction, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Carbohydrate digestion and absorption, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00615 Amlodipine [4] 13, 51, 67, 298
651 CACNA1D [30] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cellular senescence, Cardiac muscle contraction, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Carbohydrate digestion and absorption, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00616 Diltiazem [3] 51, 58, 86
652 CACNA1D [30] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cellular senescence, Cardiac muscle contraction, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Carbohydrate digestion and absorption, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00617 Nicardipine [2] 70, 86
653 CACNA1D [30] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cellular senescence, Cardiac muscle contraction, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Carbohydrate digestion and absorption, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00619 Verapamil [3] 96, 140, 167
654 CACNA1D [30] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cellular senescence, Cardiac muscle contraction, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Carbohydrate digestion and absorption, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D01173 Cilnidipine [1] 67
655 CACNA1D [30] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cellular senescence, Cardiac muscle contraction, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Carbohydrate digestion and absorption, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D01908 Nilvadipine [1] 90
656 CACNA1D [30] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cellular senescence, Cardiac muscle contraction, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Carbohydrate digestion and absorption, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D02356 Verapamil [3] 96, 140, 167
657 CACNA1D [30] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cellular senescence, Cardiac muscle contraction, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Carbohydrate digestion and absorption, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D02914 Amlodipine [4] 13, 51, 67, 298
658 CACNA1D [30] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cellular senescence, Cardiac muscle contraction, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Carbohydrate digestion and absorption, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D03830 Diltiazem [3] 51, 58, 86
659 CACNA1D [30] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cellular senescence, Cardiac muscle contraction, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Carbohydrate digestion and absorption, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D05442 Perhexiline [2] 58, 272
660 CACNA1D [30] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cellular senescence, Cardiac muscle contraction, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Carbohydrate digestion and absorption, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D07450 Amlodipine [4] 13, 51, 67, 298
661 CACNA1D [30] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cellular senescence, Cardiac muscle contraction, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Carbohydrate digestion and absorption, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D07845 Diltiazem [3] 51, 58, 86
662 CACNA1D [30] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cellular senescence, Cardiac muscle contraction, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Carbohydrate digestion and absorption, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D08270 Nicardipine [2] 70, 86
663 CACNA1D [30] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cellular senescence, Cardiac muscle contraction, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Carbohydrate digestion and absorption, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D08340 Perhexiline [2] 58, 272
664 CACNA1D [30] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cellular senescence, Cardiac muscle contraction, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Carbohydrate digestion and absorption, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D08441 Propiverine [1] 226
665 CACNA1F [23] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00349 Isradipine [1] 6
666 CACNA1F [23] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00437 Nifedipine [2] 50, 81
667 CACNA1F [23] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
668 CACNA1F [23] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00615 Amlodipine [4] 13, 51, 67, 298
669 CACNA1F [23] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00616 Diltiazem [3] 51, 58, 86
670 CACNA1F [23] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00617 Nicardipine [2] 70, 86
671 CACNA1F [23] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00619 Verapamil [3] 96, 140, 167
672 CACNA1F [23] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D01173 Cilnidipine [1] 67
673 CACNA1F [23] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D01908 Nilvadipine [1] 90
674 CACNA1F [23] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D02356 Verapamil [3] 96, 140, 167
675 CACNA1F [23] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D02914 Amlodipine [4] 13, 51, 67, 298
676 CACNA1F [23] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D03830 Diltiazem [3] 51, 58, 86
677 CACNA1F [23] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D05442 Perhexiline [2] 58, 272
678 CACNA1F [23] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D07450 Amlodipine [4] 13, 51, 67, 298
679 CACNA1F [23] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D07845 Diltiazem [3] 51, 58, 86
680 CACNA1F [23] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D08270 Nicardipine [2] 70, 86
681 CACNA1F [23] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D08340 Perhexiline [2] 58, 272
682 CACNA1F [23] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D08441 Propiverine [1] 226
683 CACNA1S [23] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00349 Isradipine [1] 6
684 CACNA1S [23] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00437 Nifedipine [2] 50, 81
685 CACNA1S [23] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
686 CACNA1S [23] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00615 Amlodipine [4] 13, 51, 67, 298
687 CACNA1S [23] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00616 Diltiazem [3] 51, 58, 86
688 CACNA1S [23] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00617 Nicardipine [2] 70, 86
689 CACNA1S [23] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D00619 Verapamil [3] 96, 140, 167
690 CACNA1S [23] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D01173 Cilnidipine [1] 67
691 CACNA1S [23] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D01908 Nilvadipine [1] 90
692 CACNA1S [23] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D02356 Verapamil [3] 96, 140, 167
693 CACNA1S [23] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D02914 Amlodipine [4] 13, 51, 67, 298
694 CACNA1S [23] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D03830 Diltiazem [3] 51, 58, 86
695 CACNA1S [23] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D05442 Perhexiline [2] 58, 272
696 CACNA1S [23] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D07450 Amlodipine [4] 13, 51, 67, 298
697 CACNA1S [23] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D07845 Diltiazem [3] 51, 58, 86
698 CACNA1S [23] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D08270 Nicardipine [2] 70, 86
699 CACNA1S [23] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D08340 Perhexiline [2] 58, 272
700 CACNA1S [23] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy D08441 Propiverine [1] 226
701 CXCR4 [11] Calcium signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, Chemokine signaling pathway, Endocytosis, Leukocyte transendothelial migration, Intestinal immune network for IgA production, Regulation of actin cytoskeleton, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer D08971 Plerixafor [6] 19, 20, 51, 65, 285, 299
702 FGF23 [10] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Melanoma, Gastric cancer D10913 Burosumab [1] 238
703 CACNA1I [6] MAPK signaling pathway, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome D00399 Valproic acid [17] 2, 3, 5, 6, 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331
704 CACNA1I [6] MAPK signaling pathway, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome D00538 Zonisamide [1] 6
705 CACNA1I [6] MAPK signaling pathway, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome D01303 Flunarizine [4] 58, 86, 149, 215
706 CACNA1I [6] MAPK signaling pathway, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome D07971 Flunarizine [4] 58, 86, 149, 215
707 CACNA1H [6] MAPK signaling pathway, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome D00399 Valproic acid [17] 2, 3, 5, 6, 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331
708 CACNA1H [6] MAPK signaling pathway, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome D00538 Zonisamide [1] 6
709 CACNA1H [6] MAPK signaling pathway, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome D01303 Flunarizine [4] 58, 86, 149, 215
710 CACNA1H [6] MAPK signaling pathway, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome D07971 Flunarizine [4] 58, 86, 149, 215
711 CACNA1G [7] MAPK signaling pathway, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome D00399 Valproic acid [17] 2, 3, 5, 6, 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331
712 CACNA1G [7] MAPK signaling pathway, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome D00538 Zonisamide [1] 6
713 CACNA1G [7] MAPK signaling pathway, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome D01303 Flunarizine [4] 58, 86, 149, 215
714 CACNA1G [7] MAPK signaling pathway, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome D07971 Flunarizine [4] 58, 86, 149, 215
715 CD38 [7] Nicotinate and nicotinamide metabolism, Metabolic pathways, Calcium signaling pathway, Hematopoietic cell lineage, Oxytocin signaling pathway, Salivary secretion, Pancreatic secretion D10777 Daratumumab [5] 16, 28, 49, 63, 222
716 CD38 [7] Nicotinate and nicotinamide metabolism, Metabolic pathways, Calcium signaling pathway, Hematopoietic cell lineage, Oxytocin signaling pathway, Salivary secretion, Pancreatic secretion D11050 Isatuximab [2] 28, 61
717 CD38 [7] Nicotinate and nicotinamide metabolism, Metabolic pathways, Calcium signaling pathway, Hematopoietic cell lineage, Oxytocin signaling pathway, Salivary secretion, Pancreatic secretion D11945 Mezagitamab [1] 66